Polycythemia Vera (PV) is a rare, long-term blood cancer where the body produces too many red blood cells, impacting around 160,000 patients in the U.S. and with a similar prevalence in Europe. Rusfertide is a revolutionary hepcidin mimetic transforming Polycythemia Vera (PV) treatment. Results highlight sustained hematocrit control, reduced phlebotomy needs, and improved patient well-being.
Takeda and Protagonist Therapeutics, Inc., today announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV). This collaboration represents a significant step forward in addressing the challenges posed by PV and brings hope for improved treatment options.
"As pioneers in the field of pharmaceutical peptide drug discovery and development, we believe that the maximum impact from our innovation and development acumen can be best achieved with the right partner at the right time," said Dinesh V. Patel, Ph.D., President and CEO of Protagonist Therapeutics. "This transformational deal allows Protagonist to focus on completion of Phase 3, while leveraging Takeda's exceptional global commercialization capabilities to immediately commence pre-commercial activities with a first-in-class new chemical entity. As we progress towards a fully integrated pharmaceutical company, this deal mitigates the inherent execution risks of a first-time commercial launch, optimizes the timing and enhances the scope for peak potential sales of rusfertide, while still allowing us to actively participate in the commercial experience and economics with a 50:50 profit split in the U.S. market."
Check out the official press release to delve into the details!